CAMBRIDGE, Mass., Jan. 13, 2025 – Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced its three-year strategic priorities, anticipated 2025 key milestones, and new in vivo preclinical proof of concept data in non- human primates editing hematopoietic stem cells (HSCs) and liver cells and in vivo delivery data in humanized mice to two additional target cell types. "Two years ago, we detailed our objective ...

Achieved in vivo preclinical proof of concept of editing hematopoietic stem cells in non-human primates as a key step toward developing a novel in vivo treatment for sickle cell disease and beta thalassemia Achieved in vivo editing of liver cells in non-human primates and in vivo delivery to two additional cell types in humanized mice Anticipated 2025 milestones include: declare two in vivo development candidates, one in HSCs and one in liver; present further in vivo HSC data; present in vivo data in one li ...

CAMBRIDGE, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading gene editing company, today announced that the Company's President and CEO Gilmore O'Neill, M.B., M.M.Sc., will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, 11:15 a.m. PT / 2:15 p.m. ET in San Francisco, CA. A live webcast of the presentation will be available on the "Investors" section of the Editas Medicine website at www.editasmedicine.com. An archived replay ...

Shares of Editas Medicine (EDIT) plunged 23.8% on Dec. 13 after it announced a strategic decision to end the development of its lead gene editing therapy, reni-cel, following the failure of an extensive search to yield a commercial partner. The company is already facing a massive cash crunch and without a partner, it is unable to sustain the development cost of reni-cel. The candidate was evaluated in a phase I/II/III RUBY study and a phase I/II EdiTHAL study for severe sickle cell disease (SCD) and transfu ...

Focus on in vivo CRISPR-edited medicines based on Editas researchers’ recent scientific progress in multiple tissues: Achieved pre-clinical in vivo proof of concept of high level HBG1/2 promoter editing and HbF induction in a humanized mouse model for treatment of sickle cell disease and beta thalassemia with a single dose of an HSC-targeted lipid nanoparticle (tLNP) formulationAchieved in vivo proof of concept of high efficiency editing in the liver in non-human primates Ending development of reni-cel afte ...

It has been about a month since the last earnings report for Editas Medicine (EDIT) . Shares have lost about 36.5% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Editas due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Editas Q3 Loss Narrower Than Expected, Revenue ...

Editas Medicine, Inc. (NASDAQ:EDIT) 7th Annual Evercore HealthCONx Conference December 3, 2024 1:20 PM ET Company Participants Erick Lucera - Executive Vice President and Chief Financial Officer Cristi Barnett - Senior Vice President, Corporate Communications and Investor Relations Conference Call Participants Liisa Bayko - Evercore ISI Liisa Bayko Okay, welcome everyone. This is Evercore’s Healthcare Conference. I'm Liisa Bayko, one of this mid-cap analysts here at Evercore, and I've been covering Editas a ...

BofA Securities downgraded Editas Medicine Inc EDIT, citing few value-driving catalysts in the near term. In its third-quarter earnings release, Editas Medicine said it engaged an investment bank to lead the process of partnering or out-licensing reni-cel (renizgamglogene autogedtemcel, previously EDIT-301). The company is developing reni-cel for sickle cell disease and transfusion-dependent Beta Thalassemia. The company is on track to share additional clinical and patient-reported outcomes data from 28 pat ...

Editas Medicine, Inc. (NASDAQ:EDIT) Stifel 2024 Healthcare Conference November 19, 2024 1:50 PM ET Company Participants Erick Lucera - Chief Financial Officer Conference Call Participants Dae Gon Ha - Stifel Dae Gon Ha All right. Thanks, everyone, for joining us for the next half hour. My name is Dae Gon Ha, one of the biotech analysts at Stifel. So with me for the next half hour, we've got Editas Medicine. So from Editas, we have Erick Lucera, Chief Financial Officer and Christine [indiscernible] VP of IR. ...

Editas Medicine (EDIT) incurred a loss of 75 cents per share in the third quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 76 cents. The company had reported a loss of 55 cents per share in the year-ago quarter.Collaboration and other research and development (R&D) revenues, which comprise the company’s top line, were $0.1 million in the reported quarter, down from $5.3 million reported in the year-ago quarter. The reported figure missed the Zacks Consensus Estimate of $7 million. Th ...